{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:45:51Z","timestamp":1773398751321,"version":"3.50.1"},"reference-count":77,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: Epidemiologic, animal, and human data suggest that progestins are potent endometrial cancer preventive agents. In the ovarian surface epithelium, progestins have been hypothesized to confer a cancer preventive effect via apoptosis and modulation of transforming growth factor-\u03b2 (TGF-\u03b2). Given that the ovarian epithelium and endometrium share a common embryologic origin and similar reproductive and hormonal risk factors for malignancy, we tested the hypothesis that progestins confer biological effects in the endometrium similar to those in the ovary.<\/jats:p><jats:p>Methods: Postmenopausal female macaques (n = 78) were randomized into four groups to receive a diet for 36 months containing no hormone versus conjugated equine estrogen (CEE), medroxyprogesterone acetate (MPA), or CEE + MPA. The endometrium was then examined immunohistochemically for treatment-specific changes using antibodies to activated caspase-3 (for apoptosis), Ki-67 (proliferation), and the TGF-\u03b21, TGF-\u03b22, and TGF-\u03b23 isoforms.<\/jats:p><jats:p>Results: Percentages of caspase-positive endometrial glandular cells were 3- to 5-fold higher in CEE + MPA\u2013treated animals compared with all others (P &amp;lt; 0.05). Caspase-expressing cells were six times more numerous in the endometrial stroma of animals treated with MPA alone relative to other groups (P &amp;lt; 0.0001). Induction of endometrial glandular cell apoptosis in the CEE + MPA\u2013treated group was associated with a dramatic increase in expression of TGF-\u03b22 and TGF-\u03b23 in the stromal compartment of the endometrium (P &amp;lt; 0.0001).<\/jats:p><jats:p>Conclusion: Progestin treatment activates chemopreventive biological effects in the endometrium that are similar to those in the ovarian surface epithelium. These data may facilitate identification of a chemopreventive approach that dramatically lessens the risk of both uterine and ovarian cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(3):578\u201384)<\/jats:p>","DOI":"10.1158\/1055-9965.epi-07-0551","type":"journal-article","created":{"date-parts":[[2008,3,18]],"date-time":"2008-03-18T18:28:24Z","timestamp":1205864904000},"page":"578-584","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Progestin Treatment Induces Apoptosis and Modulates Transforming Growth Factor-\u03b2 in the Uterine Endometrium"],"prefix":"10.1158","volume":"17","author":[{"given":"Gustavo C.","family":"Rodriguez","sequence":"first","affiliation":[{"name":"1Gynecologic Oncology and Divisions of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.J.","family":"Rimel","sequence":"additional","affiliation":[{"name":"1Gynecologic Oncology and Divisions of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Watkin","sequence":"additional","affiliation":[{"name":"2Pathology, Evanston Northwestern Healthcare, Feinberg School of Medicine, Northwestern University;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Turbov","sequence":"additional","affiliation":[{"name":"1Gynecologic Oncology and Divisions of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Barry","sequence":"additional","affiliation":[{"name":"1Gynecologic Oncology and Divisions of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Du","sequence":"additional","affiliation":[{"name":"3Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"4Gynecologic Disease Center and the U.S. Military Cancer Institute, Walter Reed Army Medical Center, Washington, District of Columbia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Cline","sequence":"additional","affiliation":[{"name":"5Department of Pathology\/Section on Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,3,18]]},"reference":[{"key":"2022060919110423400_BIB1","doi-asserted-by":"crossref","unstructured":"Amant F, Moerman P, Neven P, Timmerman D, Limbergan E, Vergote I. Endometrial Cancer. Lancet\u20082005;366:491\u2013505.","DOI":"10.1016\/S0140-6736(05)67063-8"},{"key":"2022060919110423400_BIB2","unstructured":"American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer; 2006."},{"key":"2022060919110423400_BIB3","doi-asserted-by":"crossref","unstructured":"Henderson BE, Casagrance JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. Br J Cancer\u20081983;47:749\u201356.","DOI":"10.1038\/bjc.1983.127"},{"key":"2022060919110423400_BIB4","doi-asserted-by":"crossref","unstructured":"McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol\u20081996;143:1195\u2013202.","DOI":"10.1093\/oxfordjournals.aje.a008707"},{"key":"2022060919110423400_BIB5","doi-asserted-by":"crossref","unstructured":"The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial. JAMA\u20081996;275:370\u20135.","DOI":"10.1001\/jama.275.5.370"},{"key":"2022060919110423400_BIB6","doi-asserted-by":"crossref","unstructured":"Xu W, Xiang Y-B, Zheng W, et al. Weight history and risk of endometrial cancer among Chinese women. Int J Epidemiol\u20082006;35:159\u201366.","DOI":"10.1093\/ije\/dyi223"},{"key":"2022060919110423400_BIB7","doi-asserted-by":"crossref","unstructured":"Trentham-Dietz A, Nichols H, Hampton J, Newcomb P. Weight change and risk of endometrial cancer. Int J Epidemiol\u20082006;35:151\u20138.","DOI":"10.1093\/ije\/dyi226"},{"key":"2022060919110423400_BIB8","doi-asserted-by":"crossref","unstructured":"Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control\u20082000;11:185\u201392.","DOI":"10.1023\/A:1008946825313"},{"key":"2022060919110423400_BIB9","doi-asserted-by":"crossref","unstructured":"Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17\u03b2-estradiol\/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause\u20082002;9:195\u2013207.","DOI":"10.1097\/00042192-200205000-00008"},{"key":"2022060919110423400_BIB10","doi-asserted-by":"crossref","unstructured":"Webb PM. Commentary: Weight gain, weight loss, and endometrial cancer. Int J Epidemiol\u20082006;35:166\u20138.","DOI":"10.1093\/ije\/dyi301"},{"key":"2022060919110423400_BIB11","doi-asserted-by":"crossref","unstructured":"Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer\u20082006;95:385\u20139.","DOI":"10.1038\/sj.bjc.6603260"},{"key":"2022060919110423400_BIB12","doi-asserted-by":"crossref","unstructured":"Hulka BS, Chambless LE, Kaufman DG, Fowler WC, Greenberg BG. Protection against endometrial carcinoma by combination-product oral contraceptives. J Am Med Assoc\u20081982;247:475\u20137.","DOI":"10.1001\/jama.247.4.475"},{"key":"2022060919110423400_BIB13","doi-asserted-by":"crossref","unstructured":"The Cancer and Steroid Hormone (CASH) Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. J Am Med Assoc\u20081987;257:796\u2013800.","DOI":"10.1001\/jama.257.6.796"},{"key":"2022060919110423400_BIB14","doi-asserted-by":"crossref","unstructured":"The WHO collaborative study of neoplasia and steroid contraceptives. Endometrial cancer and combined oral contraceptives. Int J Epidemiol\u20081988;17:263\u20139.","DOI":"10.1093\/ije\/17.2.263"},{"key":"2022060919110423400_BIB15","unstructured":"Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol\u20081993;82:931\u20135."},{"key":"2022060919110423400_BIB16","doi-asserted-by":"crossref","unstructured":"Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol\u20082006;103:535\u201340.","DOI":"10.1016\/j.ygyno.2006.03.046"},{"key":"2022060919110423400_BIB17","doi-asserted-by":"crossref","unstructured":"Rosenblatt KA, Thomas DB; WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. Int J Cancer\u20081991;49:870\u20134.","DOI":"10.1002\/ijc.2910490612"},{"key":"2022060919110423400_BIB18","doi-asserted-by":"crossref","unstructured":"Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol\u20082002;105:166\u20139.","DOI":"10.1016\/S0301-2115(02)00153-7"},{"key":"2022060919110423400_BIB19","doi-asserted-by":"crossref","unstructured":"Tao MH, Xu WH, Zheng W, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer\u20082006;119:2142\u20137.","DOI":"10.1002\/ijc.22081"},{"key":"2022060919110423400_BIB20","doi-asserted-by":"crossref","unstructured":"Orbo A, Rise CE, Mutter G. Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res\u20082006;66:5613\u20137.","DOI":"10.1158\/0008-5472.CAN-05-4321"},{"key":"2022060919110423400_BIB21","doi-asserted-by":"crossref","unstructured":"Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol\u20081997;90:434\u201340.","DOI":"10.1016\/S0029-7844(97)00297-4"},{"key":"2022060919110423400_BIB22","doi-asserted-by":"crossref","unstructured":"Vereide AB, Kaino T, Sager G, \u00d8rbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol\u20082005;97:740\u201350.","DOI":"10.1016\/j.ygyno.2005.02.030"},{"key":"2022060919110423400_BIB23","doi-asserted-by":"crossref","unstructured":"Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-\u03b2. J Natl Cancer Inst\u20082002;94:50\u201360.","DOI":"10.1093\/jnci\/94.1.50"},{"key":"2022060919110423400_BIB24","doi-asserted-by":"crossref","unstructured":"Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst\u20082002;94:32\u20138.","DOI":"10.1093\/jnci\/94.1.32"},{"key":"2022060919110423400_BIB25","doi-asserted-by":"crossref","unstructured":"Whittemore AS, Harris R, Itnyre J; Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Am J Epidemiol\u20081992;136:1212\u201320.","DOI":"10.1093\/oxfordjournals.aje.a116429"},{"key":"2022060919110423400_BIB26","unstructured":"Kurman RJ, editor. Blaustein's pathology of the female genital tract. 5th ed. New York: Springer-Verlag; 2002."},{"key":"2022060919110423400_BIB27","doi-asserted-by":"crossref","unstructured":"Cline JM, So\u0308derqvist G, Register TC, Williams JK, Adams MR, Von Schoultz B. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol\u20082001;29:84\u201390.","DOI":"10.1080\/019262301301418883"},{"key":"2022060919110423400_BIB28","unstructured":"Brenner RM, Slayden OD. Cyclic changes in the primate oviduct and endometrium. In: Knobil E, Neill JD, editors. The physiology of reproduction. New York (NY): Raven Press; 1994. p. 541\u201369."},{"key":"2022060919110423400_BIB29","doi-asserted-by":"crossref","unstructured":"Mordenti J. Dosage regimen design for pharmaceutical studies conducted in animals. J Pharm Sci\u20081986;75:852\u20137.","DOI":"10.1002\/jps.2600750906"},{"key":"2022060919110423400_BIB30","doi-asserted-by":"crossref","unstructured":"Yasui T, Uemura H, Tezuka M, Yamada M, Irahara M, Miura M, Aono T. Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res\u20082001;56:38\u201344.","DOI":"10.1159\/000048088"},{"key":"2022060919110423400_BIB31","doi-asserted-by":"crossref","unstructured":"Cline JM, So\u0308derqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat\u20081998;48:221\u20139.","DOI":"10.1023\/A:1005984932268"},{"key":"2022060919110423400_BIB32","doi-asserted-by":"crossref","unstructured":"Conner P, Register TC, Skoog L, Tani E, von Schoultz Cline JM. Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys. Am J Obstet Gynecol\u20082005;193:58\u201363.","DOI":"10.1016\/j.ajog.2004.11.056"},{"key":"2022060919110423400_BIB33","unstructured":"Agresti A. An introduction to categorical data analysis. New York: John Wiley & Sons; 1996."},{"key":"2022060919110423400_BIB34","doi-asserted-by":"crossref","unstructured":"Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol\u20082000;79:169\u201376.","DOI":"10.1006\/gyno.2000.5955"},{"key":"2022060919110423400_BIB35","doi-asserted-by":"crossref","unstructured":"Akcali KC, Khan SA, Moulton BC. Effect of decidualization on the expression of bax and bcl-2 in the rat uterine endometrium. Endocrinology\u20081996;137:3123\u201331.","DOI":"10.1210\/endo.137.7.8770938"},{"key":"2022060919110423400_BIB36","doi-asserted-by":"crossref","unstructured":"Hanifi-Moghaddam, Gielen SC, Kloosterboer HJ, et al. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone. J Clin Endocrinol Metabol\u20082005;90:973\u201383.","DOI":"10.1210\/jc.2004-1423"},{"key":"2022060919110423400_BIB37","doi-asserted-by":"crossref","unstructured":"Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia-precursor of endometrial cancer. Gynecol Oncol\u20082003;88:108\u201317.","DOI":"10.1016\/S0090-8258(02)00008-2"},{"key":"2022060919110423400_BIB38","doi-asserted-by":"crossref","unstructured":"Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod\u20082001;16:2103\u20138.","DOI":"10.1093\/humrep\/16.10.2103"},{"key":"2022060919110423400_BIB39","doi-asserted-by":"crossref","unstructured":"Vaskivuo TE, Stenback F, Karhumaa P, Risteli J, Dunkel L, Tapanainen JS. Apoptosis and apoptosis-related proteins in human endometrium. Mol Cell Endocrinol\u20082000;165:75\u201383.","DOI":"10.1016\/S0303-7207(00)00261-6"},{"key":"2022060919110423400_BIB40","unstructured":"Reis FM, Ribeiro MF, Maia AL, Spritzer PM. Regulation of human endometrial transforming growth factor \u03b21 and \u03b23 isoforms through menstrual cycle and medroxyprogesterone acetate treatment. Histol Histopathol\u20082002;17:739\u201345."},{"key":"2022060919110423400_BIB41","doi-asserted-by":"crossref","unstructured":"Rosario GX, Sachdeva G, Manjramkar DD, Modi DN, Meherji PK, Puri CP. Endometrial expression of immunomodulatory cytokines and their regulators during early pregnancy in bonnet monkeys (Macaca radiata). Hum Reprod\u20082005;20:3039\u201346.","DOI":"10.1093\/humrep\/dei183"},{"key":"2022060919110423400_BIB42","doi-asserted-by":"crossref","unstructured":"Okulicz WC, Ace CI, Longcope C, Tast J. Analysis of differential gene regulation in adequate versus inadequate secretory-phase endometrial complementary deoxyribonucleic acid populations from the rhesus monkey. Endocrinology\u20081996;137:4844\u201350.","DOI":"10.1210\/endo.137.11.8895355"},{"key":"2022060919110423400_BIB43","doi-asserted-by":"crossref","unstructured":"Ace CI, Okulicz WC. Differential gene regulation by estrogen and progesterone in the primate endometrium. Mol Cell Endocrinol\u20081995;115:95\u2013103.","DOI":"10.1016\/0303-7207(95)03674-V"},{"key":"2022060919110423400_BIB44","unstructured":"Haufel T, Dormann S, Hanusch J, Schwieger A, Bauer G. Three distinct roles for TGF-\u03b2 during intercellular induction of apoptosis: a review. Anticancer Res\u20081999;19:105\u201312."},{"key":"2022060919110423400_BIB45","doi-asserted-by":"crossref","unstructured":"Bursch W, Oberhammer F, Jirtle RL, et al. Transforming growth factor-\u03b21 as a signal for induction of cell death by apoptosis. Br J Cancer\u20081993;67:531\u20136.","DOI":"10.1038\/bjc.1993.98"},{"key":"2022060919110423400_BIB46","doi-asserted-by":"crossref","unstructured":"Chiarugi V, Magnelli L, Cinelli M. Complex interplay among apoptosis factors: RB, p53, E2F, TGF-\u03b2, cell cycle inhibitors and the bcl2 gene family. Pharmacol Res\u20081997;35:257\u201361.","DOI":"10.1006\/phrs.1997.0140"},{"key":"2022060919110423400_BIB47","doi-asserted-by":"crossref","unstructured":"Berchuck A, Rodriguez G, Olt GJ, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-\u03b2. Am J Obstet Gynecol\u20081992;166:676\u201384.","DOI":"10.1016\/0002-9378(92)91697-9"},{"key":"2022060919110423400_BIB48","doi-asserted-by":"crossref","unstructured":"Hurteau J, Rodriguez GC, Whitaker RS, et al. Transforming growth factor-\u03b2 inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer\u20081994;74:93\u20139.","DOI":"10.1002\/1097-0142(19940701)74:1<93::AID-CNCR2820740117>3.0.CO;2-P"},{"key":"2022060919110423400_BIB49","unstructured":"Havrilesky LJ, Hurteau JA, Whitaker RS, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor \u03b2. Cancer Res\u20081995;55:944\u20138."},{"key":"2022060919110423400_BIB50","doi-asserted-by":"crossref","unstructured":"Rotello RJ, Lieberman RC, Purchio AF, Gershenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor 1 in cultured uterine epithelial cells. Proc Natl Acad Sci U S A\u20081991;88:3412\u20135.","DOI":"10.1073\/pnas.88.8.3412"},{"key":"2022060919110423400_BIB51","doi-asserted-by":"crossref","unstructured":"El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat\u20081998;51:149\u201368.","DOI":"10.1023\/A:1006078032287"},{"key":"2022060919110423400_BIB52","doi-asserted-by":"crossref","unstructured":"James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol\u20081996;58:395\u2013401.","DOI":"10.1016\/0960-0760(96)00048-9"},{"key":"2022060919110423400_BIB53","doi-asserted-by":"crossref","unstructured":"Kyprianou N, Isaacs JT. Expression of transforming growth factor-\u03b2 in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol\u20081989;3:1515\u201322.","DOI":"10.1210\/mend-3-10-1515"},{"key":"2022060919110423400_BIB54","unstructured":"Roberson KM, Penland SN, Padilla GM, et al. Fenretinide: induction of apoptosis and endogenous transforming growth factor-\u03b2 in PC-3 prostate cancer cells. Cell Growth Differ\u20081997;8:101\u201311."},{"key":"2022060919110423400_BIB55","doi-asserted-by":"crossref","unstructured":"Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor \u03b2-dependent apoptosis in breast cancer. Cancer Res\u20082004;64:3566\u201371.","DOI":"10.1158\/0008-5472.CAN-04-0234"},{"key":"2022060919110423400_BIB56","doi-asserted-by":"crossref","unstructured":"Mishina Y, Whitworth DJ, Racine C, Behringer RR. High specificity of Mu\u0308llerian-inhibiting substance signaling in vivo. Endocrinology\u20081999;140:2084\u20138.","DOI":"10.1210\/endo.140.5.6705"},{"key":"2022060919110423400_BIB57","doi-asserted-by":"crossref","unstructured":"Voutilainen R, Miller WL. Potential relevance of Mullerian-inhibiting substance to ovarian physiology. Semin Reprod Endocrinol\u20081989;7:88\u201393.","DOI":"10.1055\/s-2007-1021385"},{"key":"2022060919110423400_BIB58","doi-asserted-by":"crossref","unstructured":"Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Mu\u0308llerian inhibiting substance and expression of the human gene in animal cells. Cell\u20081986;45:685\u201398.","DOI":"10.1016\/0092-8674(86)90783-X"},{"key":"2022060919110423400_BIB59","doi-asserted-by":"crossref","unstructured":"Byskov AG. Differentiation of mammalian embryonic gonad. Physiol Rev\u20081986;66:71\u2013117.","DOI":"10.1152\/physrev.1986.66.1.71"},{"key":"2022060919110423400_BIB60","unstructured":"Masiakos PT, MacLaughlin DT, Maheswaran S, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res\u20081999;11:3488\u201399."},{"key":"2022060919110423400_BIB61","unstructured":"Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res\u20082002;8:2640\u20136."},{"key":"2022060919110423400_BIB62","doi-asserted-by":"crossref","unstructured":"Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci U S A\u20082005;3:111\u20136.","DOI":"10.1073\/pnas.0407772101"},{"key":"2022060919110423400_BIB63","unstructured":"Sporn MB, Roberts AB, Wakefiled LM, Glick AB, Danielpour D. Transforming growth factor \u03b2 and suppression of carcinogenesis. Princess Takamatsu Symposia\u20081989;20:259\u201366."},{"key":"2022060919110423400_BIB64","unstructured":"Reiss M. Transforming growth factor-\u03b2 and cancer: a love-hate relationship? Oncol Res\u20081997;9:447\u201357."},{"key":"2022060919110423400_BIB65","doi-asserted-by":"crossref","unstructured":"Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor in human disease. N Engl J Med\u20082000;342:1350\u20138.","DOI":"10.1056\/NEJM200005043421807"},{"key":"2022060919110423400_BIB66","doi-asserted-by":"crossref","unstructured":"Narayan S, Thangasamy T, Balusu R. Transforming growth factor \u03b2 signaling in cancer. Front Biosci\u20082005;10:1135\u201345.","DOI":"10.2741\/1606"},{"key":"2022060919110423400_BIB67","doi-asserted-by":"crossref","unstructured":"Pierce DF Jr, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor \u03b21 transgene expression. Proc Natl Acad Sci U S A\u20081995;92:4254\u20138.","DOI":"10.1073\/pnas.92.10.4254"},{"key":"2022060919110423400_BIB68","unstructured":"Tang B, Bottiner E, Bagnall K, Anver M, Wakefield L. Enhanced liver and lung tumorigenesis in TGF-\u03b21 heterozygous knock-out mice following treatment with diethylnitrosamine and phenobarbital [abstract]. Proc Am Assoc Cancer Res\u20081997;38:584."},{"key":"2022060919110423400_BIB69","doi-asserted-by":"crossref","unstructured":"Lin HK, Bergmann S, Pandolfi PP. Deregulated TGF-Beat signaling in leukemogenesis. Oncogene\u20082005;24:5693\u2013700.","DOI":"10.1038\/sj.onc.1208923"},{"key":"2022060919110423400_BIB70","doi-asserted-by":"crossref","unstructured":"Izzi L, Attisano L. Ubiquitin-dependent regulation of TGF-\u03b2 signalling in cancer. Neoplasia\u20082006;8:677\u201388.","DOI":"10.1593\/neo.06472"},{"key":"2022060919110423400_BIB71","doi-asserted-by":"crossref","unstructured":"Elliot RL, Blobe GC. Role of Transforming Growth Factor \u03b2 in human cancer. J Clin Oncol\u20082005;23:2078\u201393.","DOI":"10.1200\/JCO.2005.02.047"},{"key":"2022060919110423400_BIB72","doi-asserted-by":"crossref","unstructured":"Kaklamani VG, Pasche B. Role of TGF-\u03b2 in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther\u20082004;4:649\u201361.","DOI":"10.1586\/14737140.4.4.649"},{"key":"2022060919110423400_BIB73","doi-asserted-by":"crossref","unstructured":"Park SH. Fine tuning and cross-talking of TGF-\u03b2 signal by inhibitory smads. J Biochem Mol Biol\u20082005;38:9\u201316.","DOI":"10.5483\/BMBRep.2005.38.1.009"},{"key":"2022060919110423400_BIB74","doi-asserted-by":"crossref","unstructured":"Sun SY, Hail N, Lotan R. Apoptosis as a novel target for cancer prevention. J Natl Cancer Inst\u20082004;96:662\u201372.","DOI":"10.1093\/jnci\/djh123"},{"key":"2022060919110423400_BIB75","doi-asserted-by":"crossref","unstructured":"Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)\u03b4 expression in APC(min\/+) mice proportionally to their tumor inhibitory effect: implications for the role of PPAR\u03b4 in carcinogenesis. Carcinogenesis\u20082006;27:232\u20139.","DOI":"10.1093\/carcin\/bgi221"},{"key":"2022060919110423400_BIB76","doi-asserted-by":"crossref","unstructured":"Sinicrope FA, Half E, Morris JS, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev\u20082004;13:920\u20137.","DOI":"10.1158\/1055-9965.920.13.6"},{"key":"2022060919110423400_BIB77","doi-asserted-by":"crossref","unstructured":"Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol\u20081999;11:68\u201375.","DOI":"10.1097\/00001622-199901000-00014"}],"container-title":["Cancer Epidemiology, Biomarkers &amp; Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/17\/3\/578\/1752499\/578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cebp\/article-pdf\/17\/3\/578\/1752499\/578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:11:36Z","timestamp":1684296696000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cebp\/article\/17\/3\/578\/11038\/Progestin-Treatment-Induces-Apoptosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,18]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1055-9965.epi-07-0551","relation":{},"ISSN":["1055-9965","1538-7755"],"issn-type":[{"value":"1055-9965","type":"print"},{"value":"1538-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}